Literature DB >> 30106438

Emodin induces apoptosis in human hepatocellular carcinoma HepaRG cells via the mitochondrial caspase‑dependent pathway.

Xiaoxv Dong1, Boran Ni2, Jing Fu3, Xingbin Yin1, Longtai You1, Xin Leng1, Xiao Liang4, Jian Ni1.   

Abstract

Emodin‑induced hepatotoxicity in vivo and in vitro has been gaining increasing attention. However, the exact molecular pathways underlying these effects remain poorly clarified. The aim of the present study was to evaluate the cytotoxic effect of emodin on HepaRG cells and to define the underlying mechanism. The results demonstrated that emodin evidently inhibited HepaRG cell growth in a dose‑ and time‑dependent manner by blocking cell cycle progression in the S and G2/M phase and by inducing apoptosis. Emodin treatment also resulted in generation of reactive oxygen species (ROS), which abrogated mitochondrial membrane potential (MMP). The above effects were all suppressed by antioxidants, such as N‑acetylcysteine (NAC). Further studies by western blot analysis howed that emodin upregulated p53, p21, Bax, cyclin E, cleaved caspase‑3, 8 and 9, and cleaved poly(ADP‑ribose)polymerase (PARP). However, the protein expression of Bcl‑2, cyclin A and CDK2 was downregulated. Taken together, our results suggest that emodin induces apoptosis via the mitochondrial apoptosis pathway through cell cycle arrest and ROS generation in HepaRG cells.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30106438      PMCID: PMC6111625          DOI: 10.3892/or.2018.6620

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


Introduction

Apoptosis is a highly regulated and genetically programmed cell death process. It is driven through the death receptor-mediated extrinsic pathway and mitochondrial-mediated intrinsic pathway (1–3), which plays a pivotal role in the programmed cell death of mammalian cells (4). Reactive oxygen species (ROS) plays an important role in apoptosis by regulating the intrinsic mitochondrial apoptosis pathway (5). An increase in ROS production regulates Bcl-2 family members, such as Bax and Bcl-2. Changes in the Bax/Bcl-2 ratio result in the release cytochrome c, which then activates caspase-3 and cleaves PARP, leading to cell death through the mitochondrial death pathway (6–8). Emodin (1,3,8-trihydroxy-6-methylanthraquinone) (Fig. 1) is a naturally occurring anthraquinone derivative, which is found in a variety of tradition Chinese herbs including Rheum palmatum (9), Polygonum cuspidatum (10), Polygonum multiflorum (11) and Cassia occidentalis (12). Modern pharmacological studies have revealed that emodin possesses anti-proliferative effects on various cancer cells, such as pancreatic cancer (13), breast cancer (14), hepatocellular carcinoma (15), lung carcinoma (16), gastric carcinoma (17) and prostate cancer (18). Furthermore, this drug has also been reported to exhibit antiviral (19), antibacterial (20), anti-allergic (21), anti-osteoporotic (22), anti-diabetic (23), immunosuppressive (24) and neuroprotective (25) activities. Nevertheless, an increasing number of recently published studies have reported the deleterious effects of emodin in in vivo and in vitro investigations (26,27). Panigrahi et al reported that emodin isolated from the methanol extracts of Cassia occidentalis might be one of its main hepatotoxic ingredients (28). Furthermore, an in vivo study demonstrated that emodin may be one of the primary chemical components in Rheum palmatum L. that causes hepatic and renal toxicity (29).
Figure 1.

Chemical structure of emodin (1,3,8-trihydroxy-6-methylanthraquinone).

HepaRG cells, which are derived from a human hepatocellular carcinoma, express various CYPs and possess both the metabolic characteristics of primary human hepatocytes and the growth capacity of hepatic cell lines. It is useful for evaluating drug-induced hepatotoxicity and can be considered an ideal in vitro model for cytotoxicity investigation (30,31). In the present study, we investigated the cytotoxicity of emodin in HepaRG cells and the underlying molecular mechanisms. Our data demonstrated that emodin induces apoptotic cell death in HepaRG cells through ROS production and activation of the intrinsic apoptosis pathway.

Materials and methods

Materials and antibodies

Emodin (batch no. 4887, purity >98.0%) was obtained from Shanghai Standard Biotech Co., Ltd. (Shanghai, China). Emodin was dissolved in DMSO to a stock concentration of 40 mM and stored at 4°C. MTT was purchased from Bejing Biodee Biotechnology Co., Ltd. (Beijing, China). LDH assay kit, DAPI assay kit, NAC, Annexin V-FITC apoptosis assay kit, ROS assay kit, MMP assay kit, cell cycle assay kit were purchased from Beyotime (Nanjing, China). Antibodies for Bax (1:1,000; rabbit polyclonal; cat. no. 5023T), Bcl-2 (1:1,000; mouse polyclonal; cat. no. 15071), p53 (1:1,000; mouse polyclonal; cat. no. 2524T), p21 (1:1,000; rabbit polyclonal; cat. no. 2947T), cyclin A (1:1,000; mouse polyclonal; cat. no. 4656T), cyclin E (1:1,000; mouse polyclonal; cat. no. 4129P), CDK2 (1:1,000; rabbit polyclonal; cat. no. 2546T), cleaved caspase-3 (1:1,000; rabbit polyclonal; cat. no. 9661T), cleaved caspase-9 (1:1,000; rabbit polyclonal; cat. no. 9509T), cytochrome c (1:1,000; rabbit polyclonal; cat. no. 4280T) and PARP (1:1,000; rabbit polyclonal; cat. no. 9542T; all were obtained from Cell Signaling Technology, Beverly, MA, USA.

Cell line and cell culture

The HepaRG cell line was purchased from Shanghai Guan&Dao Biological Engineering Co., Ltd., Jinan, China. The cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS), antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin). Cells were maintained at 37°C under a humidified atmosphere containing 5% CO2.

Cell viability assay

Cell viability was measured using the MTT assay as previously described (32). HepaRG cells were seeded in 96-well microplates (5×103 cells/well) and incubated at 37°C overnight. After incubation with emodin (20, 40 and 80 µM) for 24 and 48 h at 37°C, 100 µl of MTT was added into each well and incubated for 4 h at 37°C in a 5% CO2 incubator. Subsequently, DMSO (150 µl) was added to dissolve the formazan crystals. Absorbance of the formazan solution was read at 570 nm in a microplate reader (Multiskan GO; Thermo Fisher Scientific, Inc.). For the lactate dehydrogenase (LDH) assay, the cells were cultured overnight and then treated with serial concentrations of emodin for 24 h. The LDH enzyme released from cells was quantified by an LDH assay kit according to the manufacturer's protocol. The absorbance of the supernatant was measured at 490 nm by fluorescent plate reader.

DAPI staining

The occurrence of apoptosis was evaluated by DAPI staining. Cells (4.0×105 cells/well) were seeded and incubated with different concentrations of emodin for 24 h. Following treatment, the cells were washed with PBS and fixed with 4% paraformaldehyde (Sigma-Aldrich) for 15 min at room temperature, and then stained in the dark with a DAPI solution for 10 min at room temperature. Thereafter, the cells were washed with PBS and photographed under an inverted fluorescence microscopy (Olympus IX71; Olympus, Tokyo, Japan).

Annexin V/PI staining assay

Annexin V/PI staining was used to confirm the emodin-induced apoptosis in HepaRG cells (33). HepaRG cells (4.0×105 cells/well) were seeded in 6-well plates and treated with various concentrations of emodin (20, 40 and 80 µM). After 24 h, the cells were collected with trypsinization, washed with PBS and resuspended in binding buffer (295 µl). Annexin V-FITC (5 µl) and propidium iodide (PE) (10 µl) were added and incubated for 15 min at 37°C in the dark. Finally, the apoptotic cells were immediately analyzed by flow cytometry (BD FACSCanto II; BD Biosciences, San Jose, CA, USA). At least 10,000 cells per sample were acquired to ensure adequate data.

Determination of intracellular ROS

ROS generation was measured with an oxidation-sensitive probe DCFH-DA, which is cleaved by nonspecific esterases and yields highly fluorescent 2,7-dichlorofluorescein (DCF) upon oxidation by ROS. After treatment with emodin (20, 40 and 80 µM) or control medium treatment for 24 h, the cells were washed twice in PBS. Then, they were loaded with DCFH-DA (10 µM) and incubated for 30 min at 37°C in the dark (34). Thereafter, the cells were harvested and washed twice with PBS, and the oxidation-induced increase in DCF fluorescence was subsequently measured by flow cytometry.

Analysis of mitochondrial membrane potential (ΔΨm)

Changes in ΔΨm were examined with the mitochondrial-specific lipophilic cationic fluorescent dye JC-1, which is capable of selective entrance into the mitochondria. Briefly, HepaRG cells (4.0×105 cells/well) were plated in 6-well culture plates and treated with different concentrations of emodin (20, 40 and 80 µM) for 24 h at 37°C. Subsequently, the cells were collected and incubated with JC-1 (10 µM) for 30 min at 37°C in the dark. The cells were then washed twice with PBS and subsequently analyzed using flow cytometry (35).

Cell cycle analysis

HepaRG cells (4.0×105 cells/well) were incubated in 6-well plates and treated with different concentrations of emodin (20, 40 and 80 µM) for 24 h at 37°C. After treatment, the cells were collected and fixed with 70% ice-cold ethanol at 4°C at least for 24 h, and then stained with PI/RNase A staining buffer solution for 30 min at 37°C in the dark (36). The resulting suspension was passed through a nylon mesh filter and analyzed by flow cytometry.

Western blot analysis

HepaRG cells were plated in 6-well plates and treated as described above. The cells were harvested, lysed with RIPA buffer for 30 min on ice. Lysates were centrifuged at 12,000 rpm for 10 min at 4°C. Total protein concentration was determined using the bicinchoninic acid assay (BCA) protein assay kit. In a parallel experiment, cytosolic and mitochondrial extracts were prepared using the ProteoExtract® Cytosol/Mitochondria Fractionation Kit (Millipore, Billerica, MA, USA) following the manufacturer's protocol. An equal amount of proteins was separated by electrophoresis on SDS-polyacrylamide gels (SDS-PAGE) and transferred onto polyvinylidene fluoride (PVDF) membranes. The membranes were blocked with TBST buffer containing 5% skim milk for 1 h, and then incubated with specific primary antibodies overnight at 4°C. After three times washing with TBST buffer, the membranes were further incubated with the horseradish peroxidase-conjugated secondary antibodies (cat. no. 3700; Cell Signaling Technology) at room temperature for 1 h (37,38). An enhanced ECL detection system was used for visualization of target proteins (iNtRON Biotechnology, Seongnam, Korea).

Statistical analysis

All experiments were performed in triplicates, and the results are expressed as mean ± standard deviation (SD). Statistical analysis was analyzed by One-Way ANOVA analysis and LSD test using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). Differences with a probability value (P) <0.05 were considered to be statistically significant.

Results

Emodin inhibits cell viability in the HepaRG cells

MTT assay indicated that emodin inhibited the proliferation of HepaRG cells in a dose- and time-dependent manner (Fig. 2A). When HepaRG cells were treated with 80 µM of emodin, the cell viabilities were ~52.21% after 24 h of treatment, and then reduced to 40.32% after 48 h of treatment, respectively. Furthermore, emodin treatment also caused LDH leakage observed on HepaRG cells in a dose-dependent manner (Fig. 2B). To further verify emodin-induced apoptosis in HepaRG cells, we analyzed morphological nuclear changes using DAPI staining. The results showed that a significant number of cells with chromatin condensation and nuclear fragmentation were observed compared to the untreated control (Fig. 2C).
Figure 2.

Cell viability and morphology of HepaRG cells after treatment with different concentrations of emodin. (A) Cell viability was evaluated by the MTT assay. (B) The cell cytotoxicity was assessed by LDH assay. (C) The nuclear morphology of HepaRG cells was observed by DAPI staining. The arrow markers represent the apoptotic cells. Data are expressed as the mean ± SD of three separate experiments (*P<0.05, **P<0.01 vs. vehicle control). LDH, lactate dehydrogenase.

Emodin induces the apoptosis of HepaRG cells

Annexin V-FITC/PI double staining was performed to quantify emodin-induced apoptosis. The percentage of viable cells was significantly decreased after treatment with emodin for 24 h. Furthermore, both the early and late apoptotic cell populations increased 7.5- and 8.3-fold in the HepaRG cells, respectively. However, pretreatment with NAC successfully reversed the apoptosis induction (Fig. 3A and B). Thus, these results indicate that emodin appears to trigger apoptotic cell death in HepaRG cells.
Figure 3.

HepaRG cells were incubated with various concentrations of emodin for 24 h, with or without NAC pretreatment. (A) Representative image of flow cytometry detection of apoptosis with Annexin V/PI in the different groups. (B) Column bar graph of the mean cell florescence for viable, apoptotic and necrotic cells. Data are expressed as the mean ± SD of three separate experiments (*P<0.05 vs. control; #P<0.05 vs. the 80 µM emodin-treated group). NAC, N-acetylcysteine.

Emodin increases ROS generation in the HepaRG cells

ROS plays an important role in the process of cell apoptosis. To measure the effect of emodin on the ROS level, the cells were stained with DCFH-DA and analyzed by flow cytometry. Compared with the control group, the results showed that the ROS level was increased dose-dependently in HepaRG cells after emodin treatment. However, after pre-treatment with NAC for 1 h, ROS generation was significantly attenuated (Fig. 4A and B).
Figure 4.

ROS generation of HepaRG cells induced by various concentrations of emodin for 24 h, with or without NAC pretreatment. (A) Representative image of flow cytometry detection with DCFH-DA in HepaRG cells. (B) Column bar graph of the mean cell florescence for DCFH-DA. Data are expressed as the mean ± SD of three separate experiments (*P<0.05 vs. the control; #P<0.05 vs. the 80 µM emodin-treated group). ROS, reactive oxygen species; NAC, N-acetylcysteine.

Emodin reduced ΔΨm and induces cytochrome c release from mitochondria

To investigate the effect of emodin on mitochondrial functions of HepaRG cells. ΔΨm was measured using JC-1 fluorescence staining by flow cytometry. Treatment with emodin induced the loss of mitochondrial membrane potential (MMP ΔΨm) in HepaRG cells in a dose-dependent manner (Fig. 5A and B). Furthermore, we investigated the release of cytochrome c by Western blot analysis. The level of cytochrome c was significantly increased in the cytosol fraction, while markedly decreased in the mitochondria after treatment with emodin for 24 h (Fig. 5C and D). Taken together, emodin induces apoptosis through a change in MMP and regulation of apoptosis-related proteins in HepaRG cells.
Figure 5.

MMP of HepaRG cells induced by various concentrations of emodin for 24 h. (A) Representative image of flow cytometry detection with JC-1 in HepaRG cells. (B) Column bar graph of the mean cell florescence for JC-1. (C) The protein expression of cytochrome c (cytc) in mitochondria and the cytosol was measured by western blotting. β-actin and COX IV were analyzed as the internal control for the cytosolic and mitochondrial fractions, respectively. (D) The protein bands were quantified and statistically analyzed. Data for each image are expressed as the mean ± SD of three separate experiments (*P<0.05 vs. vehicle control). MMP, mitochondrial membrane potential.

Emodin arrests the cell cycle at the S and G2/M phases in HepaRG cells

To investigate the effects of emodin on cell cycle distribution, HepaRG cells were stained with PI and then analyzed by flow cytometry. Compared with the control group, after 24 h of emodin (40 µM) exposure, the percentage of cells in the S and G2/M phases increased from 31.74±2.46 to 52.12±2.00% and 6.14±1.72 to 15.65±1.79%, respectively (Fig. 6A and B). Moreover, we investigated the expression levels of the proteins involved in the S and G2/M phase progression. The results demonstrated that the expression levels of p53, p21 and cyclin E proteins were significantly increased. However, other cyclin proteins (cyclin A and CDK2) were downregulated in HepaRG cells (Fig. 6C and D). This experiment demonstrated that emodin arrested the cell cycle at the S and G2/M phases in the HepaRG cells.
Figure 6.

The cell cycle distribution of HepaRG cells induced by various concentrations of emodin for 24 h. (A) Emodin induced cell cycle arrest at the S and G2/M phases. (B) Column bar graph of each phase of the cell cycle is shown. (C) The related protein expression levels were determined by western blotting. Actin was used as an internal control. (D) The protein bands were quantified and statistically analyzed. Data for each image are expressed as the mean ± SD of three separate experiments (*P<0.05 vs. the vehicle control).

Emodin induces apoptosis through activation of the mitochondrial signaling pathway in HepaRG cells

To explore the possible mechanisms of emodin-induced apoptosis in HepaRG cells, we evaluated the expression of various proteins involved in the mitochondrial signaling pathway by Western blot analysis. We evaluated the expression of Bcl-2 family associated proteins and caspases, which are involved in the mitochondrial signaling pathway. Treatment with emodin significantly increased the expression of pro-apoptotic Bax and decreased the expression of anti-apoptotic Bcl-2 in a dose-dependent manner, thereby significantly resulting in an elevated Bax/Bcl-2 ratio. Moreover, caspases are the most important effector molecules for the execution of apoptosis. Compared with the vehicle-treated control group, emodin treatment obviously enhanced the expression of cleaved caspase-3, −9, Bax and PARP (Fig. 7A and B). These results indicate that emodin may induce apoptosis in HepaRG cells via the mitochondrial caspase-dependent pathway.
Figure 7.

The levels apoptosis-related proteins in the HepaRG cells induced by various concentrations of emodin for 24 h. (A) Expression of apoptosis-related proteins after treatment with emodin was determined. (B) The protein bands were quantified and statistically analyzed. Data for each image are expressed as the mean ± SD of three separate experiments (*P<0.05 vs. the vehicle control). Actin was used as an internal control.

Discussion

Emodin is a naturally occurring anthraquinone present in various traditional medicinal plants including Polygonum multiflorum Thunb., Polygonum cuspidatum, Rheum palmatum L. and Cassia occidentalis (9–12). Previous studies have demonstrated that emodin possessed many pharmacological properties, such as antiviral, anti-allergic, antiosteoporotic, anti-diabetic, immunosuppressive and neuroprotective activities (19–25). However, previous studies have demonstrated that emodin causes a variety of toxic effects such as genotoxicity (39), reproductive toxicity (40), nephrotoxicity (37) and hepatotoxicity (12,28,29,41,42). In the present study, we utilized a novel cell model (HepaRG cells) to investigate the cytotoxicity of emodin and the underlying molecular mechanisms. Compared with the control treatment, emodin significantly decreased the viability of HepaRG cells in a dose and time-dependent manner. DAPI and Annexin V/PI double staining further confirmed that emodin inhibited the growth of HepaRG cells in a dose-dependent manner via apoptosis, as confirmed by cell shrinkage, apoptotic body formation and DNA fragmentation. Thus, the results showed that the cytotoxic effect on HepaRG cells induced by emodin was attributed to apoptosis. ROS are generated as by-products of mitochondrial respiration or precise oxidases and play an important role in apoptosis signaling. Stimulated ROS production could result in oxidative stress and induce cellular damage (43). Emodin treatment effectively triggered production of intracellular ROS, which was reversed by pre-treatment with NAC. These results indicate that the change in intracellular ROS by emodin was at least in part related to apoptosis in the HepaRG cells. Furthermore, excessive ROS can induce oxidative DNA damage followed by cell cycle process arrest or delay (44). In the present study, we found that the mechanism of action of emodin in HepaRG cells was similar to that of aloe-emodin, suggesting that cell cycle arrest might be one of the mechanisms underlying the cytotoxic effect on HepaRG cells induced by emodin (45). Mitochondrial impairment or dysfunction could rapidly induce the inhibition of cell survival and proliferation (46). Our data suggest that emodin induced the collapse of MMP with an increased release of cytochrome c from the mitochondria into the cytosol, indicating clearly that the mitochondria play an essential role in emodin-induced apoptosis of HepaRG cells. These results are in accordance with our previous study (45), which demonstrated that aloe-emodin inhibited HepaRG proliferation by the induction of apoptosis through the intrinsic mitochondrial pathway. Apoptosis initiated by increased ROS production after emodin treatment might induce apoptosis-related protein change. Compared with the control cells, our data suggested that the treatment of HepaRG cells with emodin significantly increased the protein expression levels of p53, p21, Bax, cleaved caspases-3, and −9 and PARP, while emodin decreased Bcl-2 levels. Furthermore, emodin promoted cytochrome c release from mitochondria into the cytosol. Previous studies have shown that emodin induced apoptosis in cancer cells through the mitochondrial-dependent apoptotic pathway (47–49), which was consistent with our experiments. In addition, emodin induced hepatocellular carcinoma cell apoptosis through the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/AKT signaling pathways (15,50). To the best of our knowledge, this is the first report of emodin-induced apoptosis in HepaRG cells. Based on our data, we summarize the signaling pathways of emodin-induced apoptosis in HepaRG cells (Fig. 8). In summary, the present study demonstrated that emodin inhibited the proliferation of HepaRG cells and induced cell cycle arrest and apoptosis through the ROS-mediated mitochondrial pathway. Conversely, pre-treatment with NAC partly inhibited the emodin-induced apoptosis via the downregulation of ROS-mediated signal cascades.
Figure 8.

Schematic mechanism showing the apoptotic signaling pathway induced by emodin in HepaRG cells. ROS, reactive oxygen species; cytc, cytochrome c; MMP, mitochondrial membrane potential.

  48 in total

1.  Comparison of the antioxidant and transmembrane permeative activities of the different Polygonum cuspidatum extracts in phospholipid-based microemulsions.

Authors:  Mei-Hwa Lee; Li Kao; Chuan-Chuan Lin
Journal:  J Agric Food Chem       Date:  2011-08-11       Impact factor: 5.279

2.  Emodin induces apoptosis of lung cancer cells through ER stress and the TRIB3/NF-κB pathway.

Authors:  Jin Su; Yan Yan; Jingkun Qu; Xuewen Xue; Zi Liu; Hui Cai
Journal:  Oncol Rep       Date:  2017-02-07       Impact factor: 3.906

3.  Emodin induces apoptosis of human osteosarcoma cells via mitochondria- and endoplasmic reticulum stress-related pathways.

Authors:  Jinhe Ying; Huan Xu; Dhua Wu; Xiaoguang Wu
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line.

Authors:  Zhen-Hua Sun; Ping Bu
Journal:  Exp Ther Med       Date:  2012-03-15       Impact factor: 2.447

5.  Lipid regulation effects of Polygoni Multiflori Radix, its processed products and its major substances on steatosis human liver cell line L02.

Authors:  Minjiang Wang; Ronghua Zhao; Wangen Wang; Xiaojian Mao; Jie Yu
Journal:  J Ethnopharmacol       Date:  2011-11-20       Impact factor: 4.360

6.  Genotoxicity of the laxative drug components emodin, aloe-emodin and danthron in mammalian cells: topoisomerase II mediated?

Authors:  S O Müller; I Eckert; W K Lutz; H Stopper
Journal:  Mutat Res       Date:  1996-12-20       Impact factor: 2.433

7.  Emodin regulates glucose utilization by activating AMP-activated protein kinase.

Authors:  Parkyong Song; Jong Hyun Kim; Jaewang Ghim; Jong Hyuk Yoon; Areum Lee; Yonghoon Kwon; Hyunjung Hyun; Hyo-Youl Moon; Hueng-Sik Choi; Per-Olof Berggren; Pann-Ghill Suh; Sung Ho Ryu
Journal:  J Biol Chem       Date:  2013-01-09       Impact factor: 5.157

Review 8.  ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis.

Authors:  Benoît D'Autréaux; Michel B Toledano
Journal:  Nat Rev Mol Cell Biol       Date:  2007-10       Impact factor: 94.444

9.  Inhibition of oxidative stress in HeLa cells by chemopreventive agents.

Authors:  R S Bhimani; W Troll; D Grunberger; K Frenkel
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 13.312

10.  Emodin and Aloe-Emodin Suppress Breast Cancer Cell Proliferation through ER α Inhibition.

Authors:  Pao-Hsuan Huang; Chih-Yang Huang; Mei-Chih Chen; Yueh-Tsung Lee; Chia-Herng Yue; Hsin-Yi Wang; Ho Lin
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-24       Impact factor: 2.629

View more
  16 in total

Review 1.  The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers.

Authors:  Qing Zhang; Wen Wen Chen; Xue Sun; Die Qian; Dan Dan Tang; Li Lin Zhang; Mei Yan Li; Lin Yu Wang; Chun-Jie Wu; Wei Peng
Journal:  Int J Biol Sci       Date:  2022-05-16       Impact factor: 10.750

Review 2.  Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin.

Authors:  Esra Küpeli Akkol; Iffet Irem Tatlı; Gökçe Şeker Karatoprak; Osman Tuncay Ağar; Çiğdem Yücel; Eduardo Sobarzo-Sánchez; Raffaele Capasso
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

Review 3.  Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.

Authors:  Hua Luo; Chi Teng Vong; Hanbin Chen; Yan Gao; Peng Lyu; Ling Qiu; Mingming Zhao; Qiao Liu; Zehua Cheng; Jian Zou; Peifen Yao; Caifang Gao; Jinchao Wei; Carolina Oi Lam Ung; Shengpeng Wang; Zhangfeng Zhong; Yitao Wang
Journal:  Chin Med       Date:  2019-11-06       Impact factor: 5.455

Review 4.  Aloe and its Effects on Cancer: A Narrative Literature Review.

Authors:  Astère Manirakiza; Laurent Irakoze; Sebastien Manirakiza
Journal:  East Afr Health Res J       Date:  2021-06-11

5.  Potential Hepatotoxins Found in Herbal Medicinal Products: A Systematic Review.

Authors:  Nguyen Van Quan; Tran Dang Xuan; Rolf Teschke
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

6.  miR-573 regulates cell proliferation and apoptosis by targeting Bax in nucleus pulposus cells.

Authors:  Rui Wang; Boping Wen; Dong Sun
Journal:  Cell Mol Biol Lett       Date:  2019-03-20       Impact factor: 5.787

7.  Emodin Inhibits EBV Reactivation and Represses NPC Tumorigenesis.

Authors:  Chung-Chun Wu; Mei-Shu Chen; Yu-Jhen Cheng; Ying-Chieh Ko; Su-Fang Lin; Ing-Ming Chiu; Jen-Yang Chen
Journal:  Cancers (Basel)       Date:  2019-11-15       Impact factor: 6.639

8.  A Computational Toxicology Approach to Screen the Hepatotoxic Ingredients in Traditional Chinese Medicines: Polygonum multiflorum Thunb as a Case Study.

Authors:  Shuaibing He; Xuelian Zhang; Shan Lu; Ting Zhu; Guibo Sun; Xiaobo Sun
Journal:  Biomolecules       Date:  2019-10-07

Review 9.  Overview of Pharmacokinetics and Liver Toxicities of Radix Polygoni Multiflori.

Authors:  Dan Li; Mengbi Yang; Zhong Zuo
Journal:  Toxins (Basel)       Date:  2020-11-21       Impact factor: 4.546

Review 10.  Molecular mechanisms and associated cell signalling pathways underlying the anticancer properties of phytochemical compounds from Aloe species (Review).

Authors:  Hanna Svitina; Josias H Hamman; Chrisna Gouws
Journal:  Exp Ther Med       Date:  2021-06-08       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.